Belinostat (PXD101) , ≥98% , 414864-00-9

Synonym(s):
(2E)-N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide;(2E)-N-Hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-2-propenamide;(E)-N-Hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide

CAS NO.：414864-00-9

Empirical Formula: C15H14N2O4S

Molecular Weight: 318.35

MDL number: MFCD08064035

PRODUCT Properties

• Melting point: 142 - 145°C
• Density: 1.427±0.06 g/cm3(Predicted)
• storage temp.: Amber Vial, Refrigerator, Under inert atmosphere
• solubility: DMSO (Slightly), Methanol (Slightly)
• form: Solid
• pka: 8.31±0.10(Predicted)
• color: Off-White to Pale Orange
• Stability: Light Sensitive

Description and Uses

Belinostat is a drug which was developed by Spectrum Pharmaceuticals and is currently marketed by Onxeo as Beleodaq®. The drug, which received fast track designation by the United States Food and Drug Administration (US FDA) and was approved for the treatment of hematological malignancies and solid tumors associated with peripheral T-cell lymphoma (PTCL) in 2014, is a histone deacetylase (HDAC) inhibitor and is the third such treatment to receive accelerated approval for PTCL, the others being vorinostat (Zolinza®) and pralatrexate (Folotyn®). Although belinostat was not yet approved in Europe as of August 2014, the compound exhibits a safety profile considered to be acceptable for HDAC inhibitors–less than 25% of patients reported adverse effects and these most frequently were nausea, fatigue, pyrexia, anemia, and emesis.

Belinostat is a novel histone deacetylase 3 selective inhibitor, which protects the β cells from cytokine-induced apoptosis.

Safety

• HS Code: 29350090